CN117402768A - Lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor food and drug - Google Patents
Lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor food and drug Download PDFInfo
- Publication number
- CN117402768A CN117402768A CN202310234952.9A CN202310234952A CN117402768A CN 117402768 A CN117402768 A CN 117402768A CN 202310234952 A CN202310234952 A CN 202310234952A CN 117402768 A CN117402768 A CN 117402768A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- strain
- reuteri
- production
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 111
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 109
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 15
- 235000013305 food Nutrition 0.000 title abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 9
- 239000003814 drug Substances 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title abstract description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000006041 probiotic Substances 0.000 claims abstract description 36
- 235000018291 probiotics Nutrition 0.000 claims abstract description 36
- 230000000529 probiotic effect Effects 0.000 claims abstract description 29
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 28
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 28
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 23
- 108091005804 Peptidases Proteins 0.000 claims abstract description 13
- 239000004365 Protease Substances 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000000813 microbial effect Effects 0.000 claims description 7
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 abstract description 16
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 15
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 12
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 230000028327 secretion Effects 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 230000001603 reducing effect Effects 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 210000003608 fece Anatomy 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 230000029087 digestion Effects 0.000 abstract description 4
- 206010016946 Food allergy Diseases 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000002075 anti-alcohol Effects 0.000 abstract description 2
- 230000037303 wrinkles Effects 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 238000000855 fermentation Methods 0.000 description 14
- 230000004151 fermentation Effects 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000005526 G1 to G0 transition Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 208000029560 autism spectrum disease Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229940099596 manganese sulfate Drugs 0.000 description 3
- 235000007079 manganese sulphate Nutrition 0.000 description 3
- 239000011702 manganese sulphate Substances 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 3
- 239000001393 triammonium citrate Substances 0.000 description 3
- 235000011046 triammonium citrate Nutrition 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical compound OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 206010068306 Gastrointestinal bacterial infection Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003168 pharmaceutical polymer Polymers 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/005—Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
Abstract
The invention belongs to the technical field of probiotics and application thereof, and particularly relates to lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor food and drugs. To further develop and utilize the probiotic functions of lactobacillus reuteri, the present invention isolates a strain of lactobacillus reuteri (Limosilactobacillus reuteri) KA1, KA1 from the feces of a healthy adult, which has a variety of probiotic effects, including superior protease activity, the production and secretion of gamma-aminobutyric acid, the production and secretion of hyaluronic acid, the inhibition of alpha-glucosidase activity, and the production and secretion of reuterin. Thus, lactobacillus reuteri strain KA1 has the effects of promoting digestion and absorption of protein foods to improve protein allergy, anti-depression and anti-alcohol; the health-care food has the beneficial effects of resisting inflammation, aging and wrinkle, reducing blood sugar, resisting tumor and the like, and has important application value and economic value.
Description
Technical Field
The invention belongs to the technical field of probiotics and application thereof, and particularly relates to lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor food and drugs.
Background
Lactobacillus reuteri (Limosilactobacillus reuteri), also known as lactobacillus reuteri, belongs to one of the lactic acid bacteria, was first isolated in 1962 and is a gram-positive, non-motile, non-sporulation, catalase-negative, obligate heterofermentative facultative anaerobic bacterium. Lactobacillus reuteri is mainly colonized in gastrointestinal tracts of human beings, other vertebrates and mammals, can resist bacteria, resist inflammation and regulate immunity, further play roles in remodelling intestinal bacteria structures, enhancing intestinal barrier and regulating immunity, and also has certain anti-obesity and anti-diarrhea effects.
Lactobacillus reuteri is a microbial strain which can be used as a human health care product, is internationally recognized novel probiotic lactobacillus, and has high theoretical research and production application values. Lactobacillus reuteri is a part of the normal flora of the human body, and is an important component of the normal microbial system of the intestinal tract and is accompanied by a host for life, so that the lactobacillus reuteri has important significance for maintaining the microecological balance of the intestinal tract. Lactobacillus reuteri, also an edible lactic acid bacterium, is a probiotic lactobacillus with great potential as a probiotic in the intestinal flora, has become a hot spot of research in recent years, and is being continuously used as a probiotic for preparing probiotic preparations suitable for humans and animals.
At present, different strains of lactobacillus reuteri have been reported to have different probiotic functions: (1) antibacterial: most lactobacillus reuteri of human and poultry origin is capable of producing reuterin, which inhibits the growth of gram positive and gram negative bacteria and yeasts, fungi and protozoa. Meanwhile, lactobacillus reuteri can synthesize lactic acid, acetic acid, ethanol and other components, and has proved to be effective for gastrointestinal bacterial infection caused by helicobacter pylori, escherichia coli, clostridium difficile, salmonella and the like. In addition, lactobacillus reuteri can inhibit the growth of fungi such as candida, and the lactobacillus reuteri can metabolize phenylalanine to produce phenyllactic acid, so that the growth of fungi and moulds is inhibited. It can be seen that lactobacillus reuteri can inhibit the growth of harmful bacteria by the production of antibacterial substances, thereby exerting the effect of regulating the structure of flora. (2) anti-inflammatory: lactobacillus reuteri can produce histamine, thereby inhibiting Tumor Necrosis Factor (TNF) production by stimulated human monocytes; can also reduce the production of other pro-inflammatory cytokines and promote the production of IL-10, and exert anti-inflammatory effect, thereby improving inflammation. (3) modulating immunity: metabolites and cellular components of lactobacillus reuteri promote dendritic cell maturation and also produce hydrogen peroxide to stimulate the host immune system. (4) anti-obesity: lactobacillus reuteri JBD30l can significantly absorb free fatty acids in the intestinal tract, thereby reducing the accumulation of the free fatty acids in the intestinal tract and significantly reducing the weight of overweight adults; lactobacillus reuteri J1 can improve diet-induced obesity by modulating intestinal flora, modulating bile acid metabolism, inhibiting adipogenesis, promoting lipolysis. (5) alleviation of liver disease: lactobacillus reuteri MJM60668 can promote fat catabolism by inhibiting fat synthesis, alleviate fat accumulation in the liver and inhibit inflammation, thereby alleviating high-fat diet-induced non-alcoholic fatty liver disease; meanwhile, the bacteria can also increase the relative abundance of potential probiotics (such as lactobacillus and Acremonium bacteria) in the intestinal tract, thereby playing a role in regulating the intestinal barrier. In addition, lactobacillus reuteri DSM17938 is able to reverse the progression of alcoholic fatty liver (ALD) by improving steatosis and inflammatory cell infiltration, alleviating impaired liver function and improving fatty acid metabolism. (6) modulating neural development: pregnant women's high fat diet (MHFD) affects the development of offspring, increasing the risk of offspring suffering from neurological diseases such as Autism Spectrum Disorder (ASD), while lactobacillus reuteri can improve its social behaviour and synaptic dysfunction by increasing oxytocin levels, and can alleviate symptoms of different ASD. Studies have also demonstrated that lactobacillus reuteri can up-regulate GABA receptor gene expression, increasing its protein levels in multiple brain regions, and thus alleviating ASD-related behavior. (7) anti-tumor: lactobacillus reuteri PTCC 1655 can inhibit the progression of gastric cancer by inhibiting pathways involved in extracellular matrix degradation, and can also inhibit the progression of colon cancer by altering cellular redox balance and pro-apoptotic effects. Meanwhile, the lactobacillus reuteri FLRE5K1 can induce the production of anti-cancer cytokines such as TNF-a, INF-gamma and the like, so that the migration and the colonization of melanoma cells are inhibited, and the effect of preventing melanoma is realized.
The diversity of lactobacillus reuteri sources results in its diversity of genes and functions. However, the current studies on the separation and identification, the probiotics characteristics and the metabolic mechanism of the lactobacillus reuteri are still relatively few, which also affects the development and utilization of the lactobacillus reuteri to a certain extent. Therefore, it is necessary to make lactobacillus reuteri function better according to different sources, such as determining the efficacy according to the functions of the strain or the probiotics metabolite, and defining the application prospect. In conclusion, the research and application of the probiotic lactobacillus reuteri have a relatively wide development space.
Disclosure of Invention
In order to overcome the defects in the prior art, the lactobacillus reuteri (Limosilactobacillus reuteri) KA1 is separated from the feces of a healthy adult, and the strain KA1 has various probiotics, including protease production, gamma-aminobutyric acid production, hyaluronic acid production and the like, and has important potential application values.
In order to achieve the above purpose, the present invention is realized by the following technical scheme:
the first aspect of the invention provides a lactobacillus reuteri (Limosilactobacillus reuteri) KA1 strain, wherein the lactobacillus reuteri KA1 strain is deposited with the China center for type culture collection (China center for type culture collection) at a year of 09 and 27: cctccc No. M20221493; the 16S rDNA complete sequence of the lactobacillus reuteri KA1 strain is shown in SEQ ID No: 1.
In a second aspect, the invention provides the use of a strain of lactobacillus reuteri (Limosilactobacillus reuteri) KA1 according to the first aspect in the production of a protease.
The research shows that the probiotic lactobacillus reuteri KA1 strain can produce protease, which suggests that the lactobacillus reuteri KA1 strain is hopeful to be used for producing protease, and the characteristic of the protease is used for promoting the digestion and absorption of human body to protein in food, improving the absorption of small peptide and amino acid, resisting allergy and other fields.
In a third aspect, the invention provides the use of lactobacillus reuteri (Limosilactobacillus reuteri) KA1 strain according to the first aspect for the production of gamma-aminobutyric acid.
The research shows that the probiotic lactobacillus reuteri KA1 strain can produce gamma-aminobutyric acid (GABA), which suggests that the lactobacillus reuteri KA1 strain is expected to be used for producing GABA, and the probiotic lactobacillus reuteri KA1 strain is used for improving the sleeping quality of organisms, resisting depression, resisting anxiety, reducing blood pressure, improving lipid metabolism, enhancing memory capacity, improving brain activity and other fields through the characteristic of producing GABA.
In a fourth aspect, the invention provides the use of lactobacillus reuteri (Limosilactobacillus reuteri) KA1 strain according to the first aspect for the production of hyaluronic acid.
The research shows that the probiotics lactobacillus reuteri KA1 strain can produce Hyaluronic Acid (HA), which suggests that the lactobacillus reuteri KA1 strain is hopeful to be used for producing HA, and is used in the fields of anti-inflammation, anti-angiogenesis, anti-aging, wound inflammation promotion, healing and the like through the characteristic of producing HA.
In a fifth aspect, the invention provides the use of a strain of lactobacillus reuteri (Limosilactobacillus reuteri) KA1 according to the first aspect for the preparation of an alpha-glucosidase inhibitor.
The research shows that the probiotic lactobacillus reuteri KA1 strain can effectively inhibit the activity of alpha-glucosidase, the alpha-glucosidase is related to type 2 diabetes, and the inhibition of the alpha-glucosidase is one of methods for controlling postprandial hyperglycemia, which suggests that the lactobacillus reuteri KA1 strain is expected to be used in the fields of reducing blood sugar, inhibiting obesity and the like.
In a sixth aspect, the invention provides the use of lactobacillus reuteri (Limosilactobacillus reuteri) KA1 strain according to the first aspect for the production of reuterin.
The research shows that the probiotics lactobacillus reuteri KA1 strain can produce the reuteri, the reuteri is a broad-spectrum antibacterial substance and is also an anti-tumor effector molecule, and the application of the probiotic lactobacillus reuteri KA1 strain in the fields of bacteriostasis, anti-tumor and the like is suggested to be hopeful for producing the reuteri, and the probiotic lactobacillus reuteri KA1 strain is used for producing the reuteri through the characteristic of the reuteri.
In a seventh aspect, the invention provides a microbial agent for use in a probiotic apparatus, wherein the microbial agent comprises lactobacillus reuteri (Limosilactobacillus reuteri) KA1 strain according to the first aspect.
Preferably, the lactobacillus reuteri (Limosilactobacillus reuteri) KA1 strain is a fermented thallus mixture. The culture medium used for fermentation is MRS culture medium.
Preferably, in the field of pharmaceutical application, the microbial agent further comprises a pharmaceutically acceptable carrier and/or excipient.
More preferably, the above excipients refer to diluents, binders, lubricants, disintegrants, co-solvents, stabilizers, etc. and some pharmaceutically acceptable bases which are useful in the pharmaceutical field. The carrier is a functional pharmaceutical adjuvant available in the pharmaceutical field and comprises a surfactant, a suspending agent, an emulsifying agent and a plurality of novel pharmaceutical polymer materials, such as cyclodextrin, chitosan, polylactic acid (PLA), polyglycolic acid-polylactic acid copolymer (PLGA), hyaluronic acid and the like.
Preferably, in the field of medical application, the dosage forms of the microbial inoculum comprise injection, tablet, granule, capsule, dripping pill, sustained release agent and oral liquid preparation.
More preferably, the above-mentioned dosage forms refer to clinically usual dosage forms. Pharmaceutical formulations may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically), and if some drugs are unstable under gastric conditions, they may be formulated as enteric coated tablets.
Compared with the prior art, the invention has the beneficial effects that:
the invention separates lactobacillus reuteri (Limosilactobacillus reuteri) KA1 from the feces of a healthy adult, and the newly separated lactobacillus reuteri strain KA1 has various probiotics effects, including excellent protease activity, production and secretion of gamma-aminobutyric acid, production and secretion of hyaluronic acid, inhibition of alpha-glucosidase activity, production and secretion of reuterin (anti-tumor effector molecule). Thus, lactobacillus reuteri strain KA1 has the effects of promoting digestion and absorption of protein foods and improving protein allergy; anti-depression and anti-alcohol; anti-inflammatory, anti-aging and anti-wrinkle; reducing blood glucose; anti-tumor and other probiotic functions. Therefore, the lactobacillus reuteri strain KA1 newly separated by the invention has various probiotics effects, can be used in the fields of antidepressant, hypoglycemic, antitumor and the like, for example, can be prepared into anti-inflammatory antitumor food and medicine, and has important application value and economic value.
Drawings
FIG. 1 is a phylogenetic tree of Lactobacillus reuteri KA1 and other homologous lactic acid bacteria;
FIG. 2 shows the degradation of milk plates by Lactobacillus reuteri KA1 (left, blank; right, experimental group);
FIG. 3 shows that Lactobacillus reuteri KA1 can produce and secrete gamma-aminobutyric acid;
FIG. 4 shows that Lactobacillus reuteri KA1 can produce and secrete hyaluronic acid;
FIG. 5 is a graph showing that the secretion of a fermentation broth of Lactobacillus reuteri KA1 significantly inhibits alpha-glucosidase activity;
FIG. 6 shows that Lactobacillus reuteri KA1 can produce and secrete reuterin.
Detailed Description
The following describes the invention in more detail. The description of these embodiments is provided to assist understanding of the present invention, but is not intended to limit the present invention. In addition, the technical features of the embodiments of the present invention described below may be combined with each other as long as they do not collide with each other.
The experimental methods in the following examples, unless otherwise specified, are conventional, and the experimental materials used in the following examples, unless otherwise specified, are commercially available.
The following examples relate to the following experimental materials:
(1) Strains: lactobacillus reuteri (Limosilactobacillus reuteri) KA1 strain is isolated from feces of a healthy adult in Guangdong province by a laboratory of China university student's academy of life sciences intestinal microbiome study, and stored in a glycerol tube at-80 ℃ by freezing. In general, it is inoculated on the surface of a plate of MRS solid medium and cultured upside down in a constant temperature anaerobic incubator at 37℃for 24 hours to obtain colonies, or cultured in a constant temperature anaerobic incubator at 37℃for 24-48 hours with shaking in MRS liquid medium to obtain fermentation broth.
(2) The kit comprises: gamma-aminobutyric acid (GABA) detection kit (Cloud-Clone corp., cat: CEA900 Ge), hyaluronic acid (also known as hyaluronic acid, HA) detection kit (Cloud-Clone corp., cat: CEA182 Ge), alpha-glucosidase inhibitor screening kit (abcam, cat: ab 284520).
(3) MRS plate: 10g of beef extract, 10g of peptone, 5g of yeast extract, 2g of triammonium citrate, 5g of sodium acetate, 20g of glucose, 2g of dipotassium hydrogen phosphate, 1mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate, 15g of agar and ddH 2 Filling O to 1L, adjusting pH to 6.2-6.6, and autoclaving at 121deg.C for 20min to obtain MRS plate.
(4) MRS liquid medium: 10g of beef extract, 10g of peptone, 5g of yeast extract, 2g of triammonium citrate, 5g of sodium acetate, 20g of glucose, 2g of dipotassium hydrogen phosphate, 1mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate and ddH 2 The O is supplemented to 1L, and the pH is adjusted to 6.2-6.And autoclaving at 6,121 ℃ for 20min to prepare MRS liquid culture medium.
(5) MP plate: 10g of skimmed milk powder, 1g of sodium chloride, 10g of beef extract, 10g of peptone, 5g of yeast extract, 20g of glucose, 2g of tri-ammonium citrate, 5g of sodium acetate, 2g of dipotassium hydrogen phosphate, 0.5mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate, 15g of agar and ddH 2 Filling O to 1L, adjusting pH to 6.2-6.6, autoclaving at 121deg.C for 20min, and making into MP plate.
Example 1 isolation and characterization of Lactobacillus reuteri (Limosilactobacillus reuteri) KA1
Lactobacillus reuteri Limosilactobacillus reuteri KA1 was isolated from faeces of a healthy adult (male, 34 years old, bmi=24.4) in the sea ball region of guangdong, cantonese, china, as follows:
the fecal sample was repeatedly washed 3 times with sterile water, placed in a mortar, 500uL of sterile water was added per 100mg of fecal sample, thoroughly ground to a homogenate, and then an appropriate amount of the grinding fluid was pipetted, spread on an MRS plate, and incubated at room temperature for 3 days. The colonies to be streaked and purified in the separation experiment plates were numbered with a marker and strain numbers were marked on the plates accordingly. Colonies were picked and inoculated onto MRS plates and the strains were purified by plate streaking. If the strain cannot be separated by the method, colonies need to be picked from the enrichment plate, and the colonies are coated on the MRS plate after being subjected to gradient dilution by the MRS liquid culture medium. Reference is made to the "Berger's Manual of bacteria identification" (eighth edition) and the "manual of fungus classification identification", which identify strains belonging to bacteria first. The purified strain is obtained through preliminary separation, the strain number is KA1, and bacterial colonies of the strain are observed to be irregular, round, convex, smooth and neat in edge after 24 hours of culture.
Next, after molecular identification by 16S rDNA universal primer (27F: AGAGTTTGATCCTGGCTCAG,1492R: TACGGCTACCTTGTTACGACTT), the isolated L.reuteri KA1 strain was subjected to whole genome sequencing by Beijing Baimeike biosciences Corp. The resulting sequence 16S rDNA sequence (SEQ ID No: 1) was subjected to BLAST alignment at NCBI' S Genome database. The results show that the homology of KA1 strain with the known lactobacillus reuteri 16S rDNA sequence is >99%; and performing evolution analysis with homologous strains (FIG. 1), and confirming that strain KA1 is Lactobacillus reuteri of the same species and different strains.
Finally, strain KA1 is preserved with the following information: preservation time: 2022, 09, 27; preservation unit name: china Center for Type Culture Collection (CCTCC); deposit number: cctccc No. M20221493; deposit unit address: chinese university of Wuhan; classification naming: limosilactobacillus reuteri.
Lactobacillus reuteri is a probiotic bacterial strain approved by the country for food, has wide probiotic effects such as antibiosis, anti-inflammation, anti-tumor and the like, but different strains from different sources have different effects, which indicates that the novel lactobacillus reuteri KA1 separated from human excrement can be used as probiotic bacteria, and possibly has novel effects and functions.
L.reuteri KA116S rDNA sequence(1445bp，SEQ ID No：1)：
TGCAGTCGTACGCACTGGCCCAACTGATTGATGGTGCTTGCACCTGATTGACGATGGATCACCAGTGAGTGGCGGACGGGTGAGTAACACGTAGGTAACCTGCCCCGGAGCGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAACAACAAAAGCCACATGGCTTTTGTTTGAAAGATGGCTTTGGCTATCACTCTGGGATGGACCTGCGGTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCGATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACAATGGAACTGAGACACGGTCCATACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGGCGCAAGCCTGATGGAGCAACACCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCTGTTGTTGGAGAAGAACGTGCGTGAGAGTAACTGTTCACGCAGTGACGGTATCCAACCAGAAAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTGCTTAGGTCTGATGTGAAAGCCTTCGGCTTAACCGAAGAAGTGCATCGGAAACCGGGCGACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAGTGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGGAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATCTTGCGCTAACCTTAGAGATAAGGCGTTCCCTTCGGGGACGCAATGACAGGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTTACTAGTTGCCAGCATTAAGTTGGGCACTCTAGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGACGACGTCAGATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGTCGCAAGCTCGCGAGAGTAAGCTAATCTCTTAAAGCCGTTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGAGTTTGTAACGCCCAAAGTCGGTGGCCTAACCTTTATGGAGGAGCCGCCTA。
Example 2 function of Lactobacillus reuteri (Limosilactobacillus reuteri) KA1 and use thereof
(1) Lactobacillus reuteri KA1 strain can produce protease for degrading milk protein
The identification and measurement of the ability of lactobacillus reuteri KA1 to secrete proteolytic proteins was performed according to the agar well diffusion assay using a skim milk plate medium (MP plate). In the test, 3uL of lactobacillus reuteri KA1 strain solution with the concentration of 10Abs was added dropwise to the test group, and 3uL of blank MRS culture medium was added dropwise to the control group. The cells were cultured in an anaerobic incubator at 37℃for 3 days in an inverted manner. The results showed that KA1 significantly degraded protein and formed a distinct degradation circle (FIG. 2) compared to the control with the blank medium, indicating that Lactobacillus reuteri KA1 produced protease.
Therefore, the lactobacillus reuteri KA1 can promote the digestion and absorption of protein in food by human body and improve the absorption of small peptide and amino acid. And can be used for resisting allergy (improving food allergy caused by protein dyspepsia or non-absorption). In addition, the method can also be used for extracting protease and is applied to the production in the protease fields of food industry, washing industry and the like; can also be used in microbial feed to help animals digest and absorb nutrition, and improve the utilization rate of the feed.
(2) Lactobacillus reuteri KA1 strain can produce gamma-aminobutyric acid (GABA)
Lactobacillus reuteri KA1 cultured in MRS liquid medium to stationary phase is spread in new MRS liquid medium at dilution ratio of 1:30, bacterial suspension is collected when culturing to stationary phase for 24h, cultured thallus is collected after centrifugation at 10,000Xg and 4deg.C for 10min, and obtained thallus is obtained by buffer PBS (8 g NaCl, 0.2g KCl, 1.44g Na are weighed 2 HPO 4 、0.24g KH 2 PO 4 Dissolving in 800mL distilled water, regulating the solution to 7.2 with HCl, adding distilled water to a volume of 1L to obtain PBS buffer solution, performing lysis to obtain thallus lysate, and measuring GABA concentration in the cultured thallus by using GABA specific ELISA kit (CEA 900 Ge). The results showed that the concentration of GABA in the cell lysate of KA1 was significantly increased compared to buffer PBS used for lysing cells, and that the cumulative amount was 32.24pg/mL, indicating that Lactobacillus reuteri KA1 was able to produce gamma-aminobutyric acid in stationary phase (FIG. 3).
Gamma-aminobutyric acid is an important central nervous system inhibitory neurotransmitter, and is widely present in animals, plants and microorganisms. It has been demonstrated that GABA, a small molecular weight non-protein amino acid, is food safe and can be used as a food additive. Research shows that intake of a certain amount of GABA has the physiological effects of improving sleeping quality of organisms, resisting depression, resisting anxiety, reducing blood pressure, improving lipid metabolism, enhancing memory and brain activity, accelerating brain metabolism, strengthening liver and kidney, promoting ethanol metabolism (dispelling alcohol effect), improving climacteric syndrome and the like.
Thus, the probiotic lactobacillus reuteri KA1 strain may serve several purposes as described above by producing gamma-aminobutyric acid.
(3) Lactobacillus reuteri KA1 strain can produce and secrete Hyaluronic Acid (HA)
Lactobacillus reuteri KA1 cultured in MRS liquid medium to stationary phase was expanded into new MRS liquid medium at a dilution ratio of 1:30, bacterial suspension was collected at 24h of stationary phase, and after centrifugation at 10,000xg at 4 ℃ for 10min, the supernatant of the fermentation broth was collected, and the HA concentration of the supernatant of the fermentation broth was measured by means of hyaluronic acid (also known as hyaluronic acid, HA) specific ELISA kit (CEA 182 Ge). The results showed that the concentration of HA in the fermentation supernatant of KA1 was significantly increased compared to the medium-low concentration HA of the blank medium MRS, and the accumulated amount was 6.534ng/mL, indicating that lactobacillus reuteri KA1 can produce and secrete hyaluronic acid in the stationary phase (fig. 4).
Hyaluronic acid is a polymer which is biodegradable, biocompatible, nontoxic, and non-allergenic, and has a variety of biological functions. Has anti-inflammatory and anti-angiogenesis effects, and has strong anti-aging, moisturizing and wrinkle smoothing abilities. The anti-wrinkle agent is beneficial to skin anti-wrinkle, promotes wound anti-inflammation and healing, can be used as an anti-wrinkle agent, and has the potential of developing skin cosmetics. In addition, HA HAs high lubricating, water absorbing and retaining ability, and can affect various cell functions such as migration, adhesion and proliferation, so that HA is also widely used in biomedical fields such as ophthalmic surgery, arthritis treatment, wound healing scaffolds, tissue engineering, implant materials, and the like.
Thus, the probiotic lactobacillus reuteri KA1 strain may serve several purposes as above by producing hyaluronic acid.
(4) The fermentation liquor of lactobacillus reuteri KA1 strain can effectively inhibit the activity of alpha-glucosidase
Lactobacillus reuteri KA1 cultured in MRS liquid medium to stationary phase was expanded into new MRS liquid medium at a dilution ratio of 1:30, bacterial suspension was collected at 24h of stationary phase, and fermentation broth supernatant was collected after centrifugation at 10,000xg at 4 ℃ for 10min, and the effect of fermentation broth supernatant on the enzyme activity ability of α -glucosidase to hydrolyze glucose was measured by an α -glucosidase inhibitor screening kit (ab 284520). The results showed that the fermentation supernatant of KA1 significantly inhibited the ability of alpha-glucosidase to hydrolyze glucose compared to the non-inhibitory effect of the blank medium MRS, with an inhibition rate of about 18.63%, indicating that the fermentation broth of Lactobacillus reuteri KA1 can effectively inhibit the activity of alpha-glucosidase (FIG. 5).
Alpha-glucosidase, an enzyme that plays a role in carbohydrate breakdown, is associated with type 2 diabetes, and inhibition of alpha-glucosidase is one of the methods of controlling postprandial hyperglycemia, thereby contributing to the treatment of diabetes. Thus, α -glucosidase inhibitors help to maintain blood glucose levels and can improve diabetic complications. Furthermore, inhibition of α -glucosidase activity may control obesity.
Thus, the probiotic lactobacillus reuteri KA1 strain has an inhibitory activity on α -glucosidase, which makes it a potential hypoglycemic and obesity inhibiting probiotic.
(5) Lactobacillus reuteri KA1 strain can produce and secrete reuterin
Lactobacillus reuteri KA1 cultured in MRS liquid medium to stationary phase was expanded into the glycerol-added MRS medium (v: v=1:10) at a dilution factor of 1:30, and after 24 hours of culture, a bacterial suspension was collected, and the supernatant of the fermentation broth was collected by centrifugation at 10,000xg for 10min at 4 ℃. Then, the content of the reuterin in the supernatant was determined by condensing acrolein with tryptophan under the action of concentrated hydrochloric acid to produce a purple compound. Taking 1mL of fermentation broth, adding 0.75mL of 10mM tryptophan to dissolve in 0.05M HCL, adding 3mL of 37% concentrated hydrochloric acid, incubating at 37deg.C for 20min, and concentrating at OD 560 The yield of reuterin was determined.
The results showed that the concentration of the reuterin measured in the fermentation supernatant of strain KA1 was about 46.5ug/mL, compared to the blank medium MRS, using glycerol as a precursor material, indicating that the production and secretion of the reuterin by Lactobacillus reuteri KA1 were possible (FIG. 6).
The Reuterin (Reuterin) is a broad-spectrum antibacterial substance capable of widely inhibiting the growth of gram-positive bacteria, gram-negative bacteria, yeasts, fungi, protozoa, and the like. Meanwhile, the reuterin can change the oxidation-reduction balance of intestinal tracts, reduce proliferation and survival of colorectal cancer cells, induce selective protein oxidation and inhibit ribosome biosynthesis and protein translation. In addition, the reuterin can effectively inhibit the growth of colorectal cancer cells, and is an anti-tumor effector molecule capable of being secreted.
Thus, the probiotic lactobacillus reuteri KA1 strain can produce and secrete reuterin, which makes it a potential probiotic that can be anti-tumor.
Taken together, the novel isolated lactobacillus reuteri strain KA1 of the present invention has a variety of probiotic effects: (1) has excellent protease activity; (2) gamma-aminobutyric acid can be produced and secreted; (3) can produce and secrete hyaluronic acid; (4) can inhibit alpha-glucosidase activity; (5) The production and secretion of reuterin (an anti-tumor effector molecule) is possible. Therefore, the lactobacillus reuteri strain KA1 obtained by the novel separation has important application value and economic value.
The embodiments of the present invention have been described in detail above, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, and yet fall within the scope of the invention.
Claims (8)
1. Lactobacillus reuteri (KA 1) strain, characterized in that the lactobacillus reuteri KA1 strain was deposited with the chinese collection of typical cultures at month 09 of 2022 under the accession number: cctcrno: M20221493; the 16SrDNA complete sequence of the lactobacillus reuteri KA1 strain is shown in SEQ ID No: 1.
2. Use of lactobacillus reuteri (KA 1) strain according to claim 1 for the production of proteases.
3. Use of lactobacillus reuteri (KA 1) strain according to claim 1 for the production of gamma-aminobutyric acid.
4. Use of lactobacillus reuteri (KA 1) strain according to claim 1 for the production of hyaluronic acid.
5. Use of lactobacillus reuteri (KA 1) strain according to claim 1 for the preparation of an alpha-glucosidase inhibitor.
6. Use of lactobacillus reuteri (KA 1) strain according to claim 1 for the production of reuteri.
7. A microbial agent for use in a probiotic function, comprising the lactobacillus reuteri (KA 1) strain of claim 1.
8. A probiotic for use according to claim 7, wherein lactobacillus reuteri (KA 1) strain is a fermented cell mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310234952.9A CN117402768B (en) | 2023-03-13 | 2023-03-13 | Lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310234952.9A CN117402768B (en) | 2023-03-13 | 2023-03-13 | Lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117402768A true CN117402768A (en) | 2024-01-16 |
| CN117402768B CN117402768B (en) | 2024-03-22 |
Family
ID=89498776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310234952.9A Active CN117402768B (en) | 2023-03-13 | 2023-03-13 | Lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117402768B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110268715A1 (en) * | 2010-04-30 | 2011-11-03 | Pei-Shan Hsieh | Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing lactobacillus |
| KR20130048946A (en) * | 2011-11-03 | 2013-05-13 | 가톨릭대학교 산학협력단 | Anti-cancer composition comprising lactobacillus reuteri cs132 or culture fluid of thereof |
| CN107828703A (en) * | 2017-12-15 | 2018-03-23 | 富乐顿生物工程科技（北京）有限公司 | Space lactobacillus reuteri Fullarton 9 35 and application |
| KR20220074383A (en) * | 2020-11-27 | 2022-06-03 | 코오롱인더스트리 주식회사 | Novel strain of Lactobacillus reuteri and use thereof |
| KR20220091695A (en) * | 2020-12-23 | 2022-07-01 | 충북대학교 산학협력단 | Novel starter of Lactobacillus reuteri EFEL6901 with probiotic activity |
| CN114806929A (en) * | 2022-03-29 | 2022-07-29 | 山东凤凰生物科技股份有限公司 | Lactobacillus reuteri LR4009 capable of highly producing reuterin and application thereof |
| WO2022169933A2 (en) * | 2021-02-03 | 2022-08-11 | Dupont Nutrition Biosciences Aps | Compositions for gut health |
| WO2022222259A1 (en) * | 2021-04-18 | 2022-10-27 | 青岛蔚蓝生物股份有限公司 | Lactobacillus reuteri having improved anti-aging and hair health enhancement effects, and application thereof |
-
2023
- 2023-03-13 CN CN202310234952.9A patent/CN117402768B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110268715A1 (en) * | 2010-04-30 | 2011-11-03 | Pei-Shan Hsieh | Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing lactobacillus |
| KR20130048946A (en) * | 2011-11-03 | 2013-05-13 | 가톨릭대학교 산학협력단 | Anti-cancer composition comprising lactobacillus reuteri cs132 or culture fluid of thereof |
| CN107828703A (en) * | 2017-12-15 | 2018-03-23 | 富乐顿生物工程科技（北京）有限公司 | Space lactobacillus reuteri Fullarton 9 35 and application |
| KR20220074383A (en) * | 2020-11-27 | 2022-06-03 | 코오롱인더스트리 주식회사 | Novel strain of Lactobacillus reuteri and use thereof |
| KR20220091695A (en) * | 2020-12-23 | 2022-07-01 | 충북대학교 산학협력단 | Novel starter of Lactobacillus reuteri EFEL6901 with probiotic activity |
| WO2022169933A2 (en) * | 2021-02-03 | 2022-08-11 | Dupont Nutrition Biosciences Aps | Compositions for gut health |
| WO2022222259A1 (en) * | 2021-04-18 | 2022-10-27 | 青岛蔚蓝生物股份有限公司 | Lactobacillus reuteri having improved anti-aging and hair health enhancement effects, and application thereof |
| CN114806929A (en) * | 2022-03-29 | 2022-07-29 | 山东凤凰生物科技股份有限公司 | Lactobacillus reuteri LR4009 capable of highly producing reuterin and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杜志琳;尹望;李雪平;: "一株罗伊氏乳杆菌的分离鉴定及其益生性能研究", 饲料研究, no. 11, 7 June 2017 (2017-06-07) * |
| 毛文浩;黄丽萍;马望;赵环;张腾飞;: "罗伊氏乳酸杆菌对非小细胞肺癌患者免疫细胞功能的影响", 肿瘤基础与临床, no. 01, 20 February 2020 (2020-02-20) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117402768B (en) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019265196B2 (en) | Lactobacillus paracasei strain and use thereof | |
| CN114032193B (en) | Lactobacillus paracasei 207-27 and application thereof | |
| CN114317320B (en) | Bifidobacterium breve 207-1 and application thereof | |
| TW200944215A (en) | Lactobacillus isolates having anti-inflammatory activities and uses of the same | |
| CN110564638A (en) | Lactobacillus reuteri with probiotic characteristics and application thereof | |
| TW200406216A (en) | Novel acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol | |
| CN116814464B (en) | Fermented lactobacillus mucilaginosus JF5 and application thereof in preparation of lipid-reducing and digestion-aiding foods and medicines | |
| CN114717129B (en) | Lactobacillus rhamnosus and application thereof in preventing and relieving constipation symptoms | |
| CN109593678B (en) | Bifidobacterium longum YH295 and application thereof in preparing product for reducing abdominal obesity risk | |
| CN116555076B (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| CN114181864A (en) | Lactobacillus rhamnosus HF01 and application thereof | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN117004503B (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| CN116555074B (en) | Lactobacillus brevis JT1 and application thereof in preparation of hypoglycemic drugs | |
| CN116555075B (en) | Lactobacillus plantarum JF1 and application thereof in preparation of anti-aging food and drug | |
| CN116286519B (en) | Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines | |
| CN117343875A (en) | Lactobacillus gasseri MY5 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine | |
| CN117402768B (en) | Lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor medicines | |
| CN117286045B (en) | Bifidobacterium longum subspecies longum KS2 and application thereof in preparation of anti-aging medicines | |
| CN116574634B (en) | Streptococcus salivarius thermophilus subspecies JF2 and application thereof in preparation of anti-inflammatory and lipid-relieving food and drug | |
| CN116496938B (en) | Lactobacillus acidophilus MY2 for producing hyaluronic acid and application thereof in preparation of anti-aging and whitening food and medicines | |
| CN117384790B (en) | Pediococcus pentosaceus KS5 and application thereof in preparation of sleep-aiding drugs | |
| CN116656526B (en) | Lactobacillus plantarum JF4 and application thereof in preparation of blood sugar and cholesterol reducing foods and medicines | |
| CN116218733B (en) | Lactobacillus rhamnosus XY5 and application thereof in preparing antiallergic and digestion-promoting food and drug | |
| CN117363524B (en) | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |